Teva Pharmaceutical Industries Limited (TEVA) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Teva Pharmaceutical Industries Limited (TEVA) closed at USD 41.11 on 2026-10-15, a change of +103.2 % over the past year, with a market capitalization of USD 48.4B.

Teva Pharmaceutical Industries Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Teva Pharmaceutical Industries Limited key figures

Previous close

USD 41.11 (2026-10-15)

1-year change

+103.2 %

Market cap

USD 48.4B

Enterprise value

USD 61.6B

P/E ratio (trailing)

69.17

P/E ratio (forward)

13.45

EPS (trailing)

0.60

EPS (forward)

3.08

PEG ratio

0.71

Price to book

6.24

Revenue growth

-0.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.08

Employees

31,173

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Teva Pharmaceutical Industries Limited and compare it with other stocks.